Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Allogeneic Stem Cell Transplantation (allo-SCT) for Chronic Myelomonocytic Leukemia – a Multicentre Australian Experience: Prognostic Factors for Survival and Relapse

Ashish R. Bajel, MBBS, FRACP, FRCPA, Cameron Curley, MBBS, FRACP, FRCPA, Andrew Boon Ming Lim, MBBS, FRACP, FRCPA, Sasanka Handunnetti, MBBS, Bartlomiej Getta, MBBS,, Philip A Thompson, MBBS, FRACP, FRCPA, Matthew P.F. Wright, MBBS,FRCPA,FRACP, Matthew Greenwood, MD FRACP, FRCPA, Mark S Hertzberg, MBBS PhDFRACP FRCPA, David J. Curtis, MD, PhD, Jeffrey Szer, MBBS, FRACP, Glen A Kennedy, MBBS, FRACP, FRCPA, David Ritchie, MBBS, PhD FRACP, FRCPA

Blood (2014) 124 (21): 1927.

https://doi.org/10.1182/blood.V124.21.1927.1927

Published: 2014

Journal Articles

Choice of Conditioning Regimen Influences Risk of Thymoglobulin Infusion Reactions in Allogeneic Hematopoietic Cell Transplantation

Andrew Boon Ming Lim, MBBS, FRACP, FRCPA, Maggie Chau, BPharm(Hons), MClinPharm, Sumita Ratnasingam, BMedSci, MBBS, Kate Mason, RN, Jeffrey Szer, MBBS, FRACP, David Ritchie, MBBS, PhD FRACP, FRCPA

Blood (2014) 124 (21): 5840.

https://doi.org/10.1182/blood.V124.21.5840.5840

Published: 2014

Journal Articles

A Radio-Resistant Perforin-Expressing Lymphoid Population Controls Allogeneic T Cell Engraftment, Activation and Onset of Gvhd

Joanne E Davis, PhD, Michael Harvey, BSc(Hons), Nicholas A Gherardin, BSc(Hons), Rachel Koldej, PhD, Nicholas Huntington, PhD, Paul Neeson, PhD, Joseph A Trapani, PhD MBBS, FRACP, David Ritchie, MBBS, PhD FRACP, FRCPA

Blood (2014) 124 (21): 3805.

https://doi.org/10.1182/blood.V124.21.3805.3805

Published: 2014

Journal Articles

Intravenous Immunoglobulin Post Allogeneic Stem Cell Transplantation Is Associated with Lower Levels of CMV Reactivation

Costas K Yannakou, MBBS(Hons), Aaron J Robinson, BBiotech(Hons), MBBS, PhD, Sumita Ratnasingam, BMedSci, MBBS, Andrew Boon Ming Lim, MBBS, FRACP, FRCPA, Yvonne Panek-Hudson, RN.MN, Maggie Chau, BPharm(Hons), MClinPharm, Jeffrey Szer, BMedSc, MBBS, FRACP, David Ritchie, MBBS, PhD FRACP, FRCPA

Blood (2014) 124 (21): 2482.

https://doi.org/10.1182/blood.V124.21.2482.2482

Published: 2014

Journal Articles

Causes and Effects of Methotrexate Dose Alterations in Allogeneic Hematopoietic Cell Transplantation

Radha Ramanan, MBBS, Andrew Boon Ming Lim, MBBS, FRACP, FRCPA, Kate Mason, RN, Jeffrey Szer, MBBS, FRACP, David Ritchie, MBBS, PhD FRACP, FRCPA

Blood (2014) 124 (21): 2460.

https://doi.org/10.1182/blood.V124.21.2460.2460

Published: 2014

Journal Articles

Single-Centre Validation Of a Disease Risk Index For Estimating Survival and Relapse In Allogeneic Hematopoietic Stem Cell Transplant Recipients: Sample Size, Adequate Follow-Up, and Use Of Local Data Are Vital Considerations

Andrew B M Lim, MBBS, FRACP, FRCPA, Andrew W. Roberts, MD, PhD, Kate Mason, RN, Ashish R. Bajel, MBBS, FRACP, FRCPA, Jeffrey Szer, MBBS, David Ritchie, MBBS, PhD, FRACP, FRCPA

Blood (2013) 122 (21): 2143.

https://doi.org/10.1182/blood.V122.21.2143.2143

Published: 2013

Journal Articles

Histone Deacteylase Inhibitors (HDACi) Suppress Toll-Like Receptor-Induced Dendritic Cell Maturation and Alter Secretion But Not Gene Expression Of Polarising Cytokines By Dendritic Cells

Michael J. Dickinson, MBBS, FRACP, FRCPA, Alexander Davenport, Pasquale Petrone, H Miles Prince, MB, BS, FRACP, FRCPA, MRACMA, MD, David Ritchie, MBBS, FRACP, FRCPA, PhD, Paul Neeson, PhD

Blood (2013) 122 (21): 3495.

https://doi.org/10.1182/blood.V122.21.3495.3495

Published: 2013

Journal Articles

HLA-Class I Alleles Impact Susceptibility To EBV + Classical Hodgkin Lymphoma By Altering EBV Latent Antigen-Specific CD8 + T-Cell Immune Hierarchies

Maher K Gandhi, Rebekah M Brennan, Leesa Wockner, Pratip K Chattopadhyay, PhD, Mario Roederer, PhD, David A. Price, MD, PhD, David K Cole, PhD, Brekhna Hassan, Konrad Beck, Alycia Thornton, David Gottlieb, MB, PhD, FRCPA, FRACP, David Ritchie, MBBS, PhD, FRACP, FRCPA, John F Seymour, MBBS, PhD, FRACP, Gayathri Kumarasinghe, MB BS, FRACP, Scott R Burrows, PhD, Kimberley Jones, BSc

Blood (2013) 122 (21): 630.

https://doi.org/10.1182/blood.V122.21.630.630

Published: 2013

Journal Articles

CD57+ NK CELLS ARE Increased In Patients With Multiple Myeloma and ARE Primed Effectors For ADCC, But NOT Natural Cytotoxicty

Andy K Hsu, PhD, Nick Gherardin, BSc Hons, Hang Quach, MBBS MD, Simon J. Harrison, MBBS MRCP (uk) MRCPath (uk) PhD, H Miles Prince, MB, BS, FRACP, FRCPA, MRACMA, MD, David Ritchie, MBBS, FRACP, FRCPA, PhD, Paul Neeson, PhD

Blood (2013) 122 (21): 1904.

https://doi.org/10.1182/blood.V122.21.1904.1904

Published: 2013

Journal Articles

Screening With Spirometry Is A Useful Predictor Of Later Development Of Non-Infectious Pulmonary Syndromes In Patients Undergoing Allogeneic Stem Cell Transplantation

Thompson A Philip, MBBS, FRACP, FRCPA, Andrew B M Lim, MBBS, FRACP, FRCPA, Mark Tacey, Ramzi Hijazi, MBBS, Ashley P. Ng, MBBS, BMedSc, PhD, FRACP, FRCPA, Jeffrey Szer, BMedSc, MBBS, FRACP, David Ritchie, MBBS, PhD, FRACP, FRCPA, Ashish R. Bajel, MBBS, FRACP, FRCPA

Blood (2013) 122 (21): 4603.

https://doi.org/10.1182/blood.V122.21.4603.4603

Published: 2013

Journal Articles

Lack Of Benefit From Surveillance PET-CT In Transformed Indolent Lymphoma (TrIL) In Complete Metabolic Remission (CMR) Following Therapy

Chan Y Cheah, MBBS, FRACP, FRCPA, Michael J. Dickinson, MBBS, FRACP, FRCPA, Anupkumar George, MBBS FRACP FRCPA, Michael S Hofman, MBBS FRACP FAANMS, Kate Burbury, MBBS, FRACP, FRCPA, DPhil, David Ritchie, MBBS, FRACP, FRCPA, PhD, H Miles Prince, MB, BS, FRACP, FRCPA, MRACMA, MD, Kirsten Herbert, MD, BSci(Med), FRACP, PhD, Max Wolf, MBBS, FRACP, FRCPA, Elchanan H. Januszewicz, MBBS FRACP FRCPA, Dennis A Carney, MBBS FRACP FRCPA, Simon J. Harrison, MBBS MRCP (uk) MRCPath (uk) PhD, Constantine S Tam, MBBS, FRACP, FRCPA, MD, John F. Seymour, MBBS, FRACP, PhD

Blood (2013) 122 (21): 1796.

https://doi.org/10.1182/blood.V122.21.1796.1796

Published: 2013

Journal Articles

Surveillance PET-CT Scanning Is Useful in the First 18 Months Following Completion of Therapy for Patients with Diffuse Large B-Cell Lymphoma with IPI≥3.

Chan Y Cheah, MBBS, FRACP, FRCPA, Michael S Hofman, MBBS FRACP, Michael J. Dickinson, MBBS, FRACP, FRCPA, Andrew Wirth, MBBS, FRANZCR, David A Westerman, MBBS, FRACP, FRCPA, FFSc, Simon J. Harrison, MBBS MRCP (uk) MRCPath (uk) PhD, Kate Burbury, MBBS, FRACP, FRCPA, DPhil, Max Wolf, MBBS, FRACP, FRCPA, Elchanan H. Januszewicz, MBBS FRACP FRCPA, Kirsten Herbert, MD, BSci(Med), FRACP, PhD, Miles Prince, MD, FRACP, FRCPA, Dennis A Carney, MBBS FRACP FRCPA, David Ritchie, MBBS, FRACP, FRCPA, PhD, Rodney Hicks, MB BS, MD, FRACP, John F Seymour, MB, BS, PhD, FRACP

Blood (2012) 120 (21): 2652.

https://doi.org/10.1182/blood.V120.21.2652.2652

Published: 2012

Journal Articles

Autologous Peripheral Blood T Lymphocytes Transduced with An Anti LewisY Chimeric Receptor Gene Persist In Patients with Lewis y Positive Acute Myeloid Leukaemia and Show Changes In Functional Polarization After Adoptive Transfer,

Paul Neeson, PhD, Amit S Khot, MBBS, MD, MRCP, FRCPath, Stefan Peinert, MD, Tsin Y Tai, MSc, Karen Chen, Kellie Tainton, BSc, Dominic Wall, PhD, Dirk Hoenemann, MD, Michael H Kershaw, PhD, Jennifer Westwood, Joe Trapani, PhD, Mark J Smyth, PhD, Phillip Darcy, PhD, Andrew Scott, PhD, Lucy Kravets, BSc, Jill Davison, RN, Michael J. Dickinson, MBBS, FRACP, FRCPA, David Ritchie, MBBS, FRACP, FRCPA, PhD, Miles Prince, MD, FRACP, FRCPA

Blood (2011) 118 (21): 4180.

https://doi.org/10.1182/blood.V118.21.4180.4180

Published: 2011

Journal Articles

Natural Killer Cell Adoptive Immunotherapy Is Hampered by A Rapid Development of NK Cell Dysfunction Characterized by Loss of Effector Mechanisms and Downregulation of the Transcription Factors T-Bet and Eomesodermin; Definition and Possible Mechanism of NK Cell Exhaustion

Saar I. Gill, MBBS, FRACP, Adrianne E Vasey, BS, Jeanette B Baker, PhD, Aaron Smith, BS, Holbrook E Kohrt, MD, Mareike Florek, MD, David Ritchie, MBBS, FRACP, FRCPA, PhD, Robert S Negrin, MD

Blood (2011) 118 (21): 1000.

https://doi.org/10.1182/blood.V118.21.1000.1000

Published: 2011

Journal Articles

Low Dose Lenalidomide and Dexamethasone Induction Followed by Autologous Transplantation In Untreated Patients with Myeloma Is Associated with High Response Rates and Preservation of CD8, but Not CD4 or NK Cellular Immunity

Simon J. Harrison, MBBS MRCP (uk) MRCPath (uk) PhD, Amit S Khot, MBBS, MD, MRCP (UK), FRCPath, Tsin Tsin, Andy Hsu, PhD, Karen Chen, Maureen Loudovaris, Paul Neeson, PhD, Dominic Wall, PhD, Rebecca Sedunary, H. Miles Prince, MBBS, FRACP, FRCPA, MD, David Ritchie, MBBS, FRACP, FRCPA, PhD

Blood (2011) 118 (21): 1862.

https://doi.org/10.1182/blood.V118.21.1862.1862

Published: 2011

Journal Articles

N-Methyl-2-Pyrrolidone Is a Biologically Active Thalidomide Subunit with In Vivo anti-Myeloma Properties

Jake Shortt, FRACP, FRCPA, Andy Hsu, PhD, Geoffrey M Matthews, PhD, Marta Chesi, P.Leif Bergsagel, MD, Grant A. McArthur, MD, PhD, FRACP, MBBS, Paul Neeson, PhD, David Ritchie, MBBS, FRACP, FRCPA, Ricky W Johnstone, PhD

Blood (2010) 116 (21): 4082.

https://doi.org/10.1182/blood.V116.21.4082.4082

Published: 2010

Journal Articles

Novel Thrombogenic Biomarkers In Patients with Relapsed/Refractory Multiple Myeloma (MM) Treated with Lenalidomide (LEN) and Dexamethasone (Dex) Therapy

Kate Burbury, MBBS, FRACP, FRCPA, DPhil, Peter C Gambell, Amanda Choo, Jennifer Curnow, MBBS, PhD, FRACP, FRCPA, Kevin Lynch, MBBS, Simon J. Harrison, MD, PhD, Hang Quach, David Ritchie, MBBS, FRACP, FRCPA, Miles Prince, MD, FRACP, FRCPA, David Alan A Westerman, MBBS, FRACP, FRCPA

Blood (2010) 116 (21): 3187.

https://doi.org/10.1182/blood.V116.21.3187.3187

Published: 2010

Journal Articles

Lower-Dose Lenalidomide and Dexamethasone Reduces Toxicity without Compromising Efficacy In Patients with Relapsed/Refractory Myeloma, Who Are Aged ≥60 Years or Have Renal Impairment: Planned Interim Results of a Prospective Multicentre Phase II Trial

Hang Quach, MBBS, FRACP, FRCPA, MD, Liam Fernyhough, BMBS, BMediSci, FRACP, FRCPA, Ross Henderson, Gillian Corbett, Kevin Lynch, MBBS, David Ritchie, MBBS, FRACP, FRCPA, PhD, Simon J. Harrison, MD, PhD, H. Miles Prince, MBBS, FRACP, FRCPA, MD

Blood (2010) 116 (21): 1961.

https://doi.org/10.1182/blood.V116.21.1961.1961

Published: 2010

Journal Articles

Safety and Efficacy of the Combination of Bortezomib with the Deacetylase Inhibitor Romidepsin in Patients with Relapsed or Refractory Multiple Myeloma: Preliminary Results of a Phase I Trial.

Miles Prince, MBBS, Hang Quach, MBBS, Paul Neeson, MBBS, Mitch Keegan, Michael Copeman, MBBS, Stefan Peinert, MBBS, Mark Bishton, MBBS, Max Wolf, MBBS, David Ritchie, MBBS, John F. Seymour, MBBS, Dennis Carney, MBBS, David Westerman, MBBS, Simon Harrison, MBBS

Blood (2007) 110 (11): 1167.

https://doi.org/10.1182/blood.V110.11.1167.1167

Published: 2007

Journal Articles

A Comparison of Acute and Delayed Infection Rates among Patients with Indolent Lymphoid Malignancies Receiving Fludarabine(F) and Cyclophosphamide(C) with or without Rituximab(R).

Constantine S. Tam, MBBS, John Francis Seymour, MBBS, Michael Brown, RN, Philip Campbell, MBBS, John D. Scarlett, MBBS, Craig Underhill, MBBS, David Ritchie, MBBS, Rodney Bond, MBBS, Andrew Grigg, MBBS

Blood (2004) 104 (11): 3313.

https://doi.org/10.1182/blood.V104.11.3313.3313

Published: 2004

NARROW

Allogeneic Stem Cell Transplantation (allo-SCT) for Chronic Myelomonocytic Leukemia – a Multicentre Australian Experience: Prognostic Factors for Survival and Relapse

Choice of Conditioning Regimen Influences Risk of Thymoglobulin Infusion Reactions in Allogeneic Hematopoietic Cell Transplantation

A Radio-Resistant Perforin-Expressing Lymphoid Population Controls Allogeneic T Cell Engraftment, Activation and Onset of Gvhd

Intravenous Immunoglobulin Post Allogeneic Stem Cell Transplantation Is Associated with Lower Levels of CMV Reactivation

Causes and Effects of Methotrexate Dose Alterations in Allogeneic Hematopoietic Cell Transplantation

Single-Centre Validation Of a Disease Risk Index For Estimating Survival and Relapse In Allogeneic Hematopoietic Stem Cell Transplant Recipients: Sample Size, Adequate Follow-Up, and Use Of Local Data Are Vital Considerations

Histone Deacteylase Inhibitors (HDACi) Suppress Toll-Like Receptor-Induced Dendritic Cell Maturation and Alter Secretion But Not Gene Expression Of Polarising Cytokines By Dendritic Cells

HLA-Class I Alleles Impact Susceptibility To EBV + Classical Hodgkin Lymphoma By Altering EBV Latent Antigen-Specific CD8 + T-Cell Immune Hierarchies

CD57+ NK CELLS ARE Increased In Patients With Multiple Myeloma and ARE Primed Effectors For ADCC, But NOT Natural Cytotoxicty

Screening With Spirometry Is A Useful Predictor Of Later Development Of Non-Infectious Pulmonary Syndromes In Patients Undergoing Allogeneic Stem Cell Transplantation

Lack Of Benefit From Surveillance PET-CT In Transformed Indolent Lymphoma (TrIL) In Complete Metabolic Remission (CMR) Following Therapy

Surveillance PET-CT Scanning Is Useful in the First 18 Months Following Completion of Therapy for Patients with Diffuse Large B-Cell Lymphoma with IPI≥3.

Autologous Peripheral Blood T Lymphocytes Transduced with An Anti LewisY Chimeric Receptor Gene Persist In Patients with Lewis y Positive Acute Myeloid Leukaemia and Show Changes In Functional Polarization After Adoptive Transfer,

Natural Killer Cell Adoptive Immunotherapy Is Hampered by A Rapid Development of NK Cell Dysfunction Characterized by Loss of Effector Mechanisms and Downregulation of the Transcription Factors T-Bet and Eomesodermin; Definition and Possible Mechanism of NK Cell Exhaustion

Low Dose Lenalidomide and Dexamethasone Induction Followed by Autologous Transplantation In Untreated Patients with Myeloma Is Associated with High Response Rates and Preservation of CD8, but Not CD4 or NK Cellular Immunity

N-Methyl-2-Pyrrolidone Is a Biologically Active Thalidomide Subunit with In Vivo anti-Myeloma Properties

Novel Thrombogenic Biomarkers In Patients with Relapsed/Refractory Multiple Myeloma (MM) Treated with Lenalidomide (LEN) and Dexamethasone (Dex) Therapy

Lower-Dose Lenalidomide and Dexamethasone Reduces Toxicity without Compromising Efficacy In Patients with Relapsed/Refractory Myeloma, Who Are Aged ≥60 Years or Have Renal Impairment: Planned Interim Results of a Prospective Multicentre Phase II Trial

Safety and Efficacy of the Combination of Bortezomib with the Deacetylase Inhibitor Romidepsin in Patients with Relapsed or Refractory Multiple Myeloma: Preliminary Results of a Phase I Trial.

A Comparison of Acute and Delayed Infection Rates among Patients with Indolent Lymphoid Malignancies Receiving Fludarabine(F) and Cyclophosphamide(C) with or without Rituximab(R).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only